In our lab, a synthetic construct that fused the CD8α extracellular domain to a MyD88 intracellular domain, normally downstream of innate immune receptors, resulted in enhanced anti-tumor CD8 T cell function in mouse models (122). Here, CD8A is linked to neoplasm.